Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology.
Martin-Castillo
B
B
Dorca
J
J
Vazquez-Martin
A
A
Oliveras-Ferraros
C
C
Lopez-Bonet
E
E
Garcia
M
M
Del Barco
S
S
Menendez
J A
JA
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D017322:Clinical Trials, Phase II as Topic; D005260:Female; D006801:Humans; D007558:Italy; D008687:Metformin / Q000627:therapeutic use*; D020360:Neoadjuvant Therapy; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000235:genetics; D057170:Translational Research, Biomedical; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008687:Metformin; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab